secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001193125-24-059364
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech Q4 net loss $26.2M; Phase 3 melanoma trial enrollment complete, interim ORR analysis expected Q3 2024
--------------------------------------------------------------------------------

- Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.
- Cash $143.2M at Dec 31, 2023; operational runway projected into Q4 2025.
- Completed enrollment of 380 patients in pivotal Phase 3 trial of IO102-IO103 + Keytruda in advanced melanoma.
- Planned interim ORR analysis from first 225 patients expected in Q3 2024; PFS primary endpoint anticipated H2 2025.
- First patient dosed in Phase 2 basket trial of IO102-IO103 neoadjuvant/adjuvant in resectable solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/0001193125-24-059364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/d747385d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-059364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer